Double-blind comparison of pramipexole and bromocriptine treatment with placebo in advanced Parkinson's disease. International Pramipexole-Bromocriptine Study Group.

@article{Guttman1997DoubleblindCO,
  title={Double-blind comparison of pramipexole and bromocriptine treatment with placebo in advanced Parkinson's disease. International Pramipexole-Bromocriptine Study Group.},
  author={Mark Guttman},
  journal={Neurology},
  year={1997},
  volume={49 4},
  pages={1060-5}
}
Pramipexole is a new, selective, nonergoline dopamine agonist that acts on D2 and preferentially on D3 dopamine receptors. Phase II and III clinical trials have shown this drug to be useful in treating both early and advanced Parkinson's disease (PD) patients. A double-blind, randomized, multicenter study was performed to compare the safety, tolerance, and efficacy of pramipexole versus placebo in patients with advanced PD with motor fluctuations. A bromocriptine treatment group was included to… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 70 extracted citations

Similar Papers

Loading similar papers…